Global and regional estimates of preeclampsia and eclampsia: a systematic review.
Edgardo Abalos, Cristina Cuesta, Ana L Grosso...
https://pubmed.ncbi.nlm.nih.gov/23746796/Actively Recruiting
Led by Lina Bergman · Updated on 2026-09-28
294
Participants Needed
18
Research Sites
104 weeks
Total Duration
Preterm preeclampsia is a serious condition affecting both mothers and their babies, often leading to early delivery to protect health. This trial is investigating whether metformin, a common diabetes medication, can safely delay delivery, reduce the time newborns spend in intensive care, and increase birthweight in a Nordic population. The study builds on prior research suggesting metformin may modify disease progression and improve outcomes for preterm preeclampsia. Participants will be randomly assigned to receive either extended-release metformin tablets, starting with 500 mg three times daily and potentially increasing to 1 gram three times daily as tolerated, or placebo tablets with the same dosing schedule. Treatment continues until delivery. Participants will keep a diary to track medication adherence, and standard care for preeclampsia will continue alongside the study treatment. During the study, participants will be monitored from randomization until delivery to measure how long pregnancy is prolonged. After birth, researchers will track how long newborns require neonatal care and record birthweight. Follow-up assessments of mothers and children will occur two years after birth. The total participation period varies depending on delivery timing, with data collection focusing on pregnancy duration and neonatal outcomes.
CONDITIONS
PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia
L
Lina Bergman, Associate Professor
P
Pia Gudmundsson, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Lina Bergman
Lead Sponsor
The Swedish Research Council
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - From enrollment until delivery
Participants take either metformin extended-release tablets or placebo orally, starting at 500 mg three times daily and increasing as tolerated up to 1 gram three times daily. Treatment continues until delivery alongside routine care for preeclampsia.
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Edgardo Abalos, Cristina Cuesta, Ana L Grosso...
https://pubmed.ncbi.nlm.nih.gov/23746796/Catherine A Cluver, Richard Hiscock, Eric H Decloedt...
https://pubmed.ncbi.nlm.nih.gov/34551918/Fuchuan Wang, Guangming Cao, Wei Yi...
https://pubmed.ncbi.nlm.nih.gov/31886236/Jilin Hu, Jinman Zhang, Baosheng Zhu
https://pubmed.ncbi.nlm.nih.gov/31334867/Lucy C Chappell, Catherine A Cluver, John Kingdom...
https://pubmed.ncbi.nlm.nih.gov/34051884/Fiona C Brownfoot, Roxanne Hastie, Natalie J Hannan...
https://pubmed.ncbi.nlm.nih.gov/26721779/Lina Bergman
Lead Sponsor
The Swedish Research Council
Collaborating Sponsor